DSM reports Q1 2015 results
(Thomson Reuters ONE) -
* Sales of ?1,886 million, up 11%, including 2% organic sales growth
* EBITDA up 4% to ?248 million
* Nutrition delivered good organic growth of 4%, driven by volumes in animal
nutrition
* Performance Materials continued to improve EBITDA through higher volumes and
margins
* Cash from continuing operating activities improved to ?84 million (Q1 2014:
?11 million)
* Non-cash impairment of ?130 million (after tax) related to the partnership
for Polymer Intermediates and Composite Resins announced in March, leading
to a net loss after exceptional items
* Outlook 2015 updated for positive foreign exchange developments
Royal DSM, the Life Sciences and Materials Sciences company, today reported its
results for Q1 2015. DSM reported sales of ?1,886 million, an 11% increase
versus Q1 2014, due to 3% higher volumes, 1% lower prices and 9% foreign
exchange effects. DSM delivered an increased EBITDA of ?248 million compared to
?239 million in Q1 2014. The increase in operating working capital of ?199
million to ?2,102 million at the end of Q1 2015 was entirely due to the foreign
exchange translation effect. Cash operating working capital remained flat,
contrary to usual seasonality.
Commenting on the results, Feike Sijbesma, CEO/Chairman of the DSM Managing
Board, said:
"DSM delivered higher results in Q1 2015 compared to prior year, driven by
higher volumes in both Nutrition and Performance Materials. Nutrition delivered
mixed results with good volume growth in animal nutrition, partly offset by low
prices in vitamin E and weak performance in human nutrition. Performance
Materials had another strong quarter with higher volumes and margins. The mix of
foreign currencies had an overall positive impact on both clusters.
In Q1 we announced a partnership with CVC Capital Partners for Polymer
Intermediates and Composite Resins, a significant step in further optimizing our
portfolio and reducing our cyclicality. This strategic action will enable us to
focus fully on improving the operational performance of our core businesses
while capitalizing on the longer term potential for value creation of our
various partnerships.
We are progressing well with setting up a number of efficiency improvement and
cost reduction programs especially in Nutrition and in all support functions
across the company.
DSM aims to deliver an EBITDA in 2015 ahead of 2014, the increase mainly driven
by positive foreign exchange effects."
Sales, EBITDA, operating working capital and cash flow refer to continuing
operations.
Key figures
In this report:
* 'Organic sales growth' is the total impact of volume and price/mix;
* 'Discontinued operations' comprises net sales and operating profit (before
depreciation and amortization) of DSM Pharmaceutical Products up to and
including 10 March 2014 as well as DSM Fibre Intermediates and DSM Composite
Resins up to and including Q1 2015;
* 'Core net profit' is the net profit from continuing operations before
exceptional items and before acquisition related (intangible) asset
amortization.
Note: all tables are available in the attached Press release-PDF
Review by cluster
Nutrition
Sales in the first quarter increased by 15% compared to Q1 2014. Organic sales
growth was 4% compared to Q1 2014 as a result of 3% higher volumes and 1% higher
prices. Good volume growth in animal nutrition was partly offset by lower
vitamin E prices and by weakness in human nutrition. Currencies had an 11%
positive impact on sales.
EBITDA for Q1 was ?195 million, down 4% from Q1 2014. Higher volumes in animal
nutrition were offset by lower vitamin E prices, lower volumes in human
nutrition, intensified marketing and sales activities as well as actions to
reduce inventory levels. These factors and the relative higher share of animal
nutrition impacted the EBITDA margin. Positive effects of foreign exchange
rates, especially the US dollar, were partly offset by the negative impact of
the Swiss franc.
Animal Nutrition and Health net sales were ?574 million in Q1, a 23% increase
versus the ?467 million in Q1 2014. Organic sales growth in Q1 was 14%, entirely
driven by higher volumes. This development reflects the continued positive
growth momentum throughout 2014 versus a slow start in Q1 2014. Premixes showed
strong growth and Tortuga continued to develop well and delivered a strong
quarter.
Vitamin E prices were significantly lower compared to Q1 2014. This negative
price effect of more than ?20 million was compensated by higher prices for other
ingredients. However, as a substantial part of these other ingredients are in-
sourced for DSM's premix activities and as such these increased prices only have
a limited EBITDA effect.
Human Nutrition & Health net sales increased by 7% to ?452 million versus ?422
million in Q1 2014. Volumes declined 6% and prices were flat while currencies
had a positive effect of 13%. However, compared to Q4 2014, Q1 showed a positive
organic sales growth of 7%, breaking the trend of successive sales declines over
the last three quarters of 2014.
The weakness in volumes was broadly across expected product categories, in
particular low sales in fish oil based Omega 3 dietary supplements in the US.
DSM is addressing organic growth in human nutrition with intensified marketing
and sales activities and organizational changes.
Food & Beverage markets in developed economies as well as retail sales of
vitamin-based dietary supplements in the US showed early signs of improvement.
Volume growth in infant nutrition has normalized since Q4 2014, albeit at lower
than historic growth rates. I-Health enjoyed strong sales growth.
DSM Food Specialties delivered a solid performance in Q1, with good organic
growth in enzymes and cultures. Issues around manufacturing performance in
savory ingredients and cultures reported in Q4 2014 have been resolved.
Performance Materials
Organic sales development in Q1 amounted to -1% compared to Q1 2014 as a result
of 3% volume growth and 4% lower prices reflecting lower raw materials costs.
Sales benefited from positive currency effects of 8%.
DSM Engineering Plastics showed good volume growth. Sales were further supported
by a substantial FX effect, which more than compensated for lower prices in the
polyamide 6 value chain.
Business conditions in DSM Dyneema remained favorable, although organic sales in
the quarter were flat due to timing of orders.
In DSM Resins and Functional Materials volumes were flat. Higher volumes in
coating resins were offset by lower volumes in functional materials. Positive FX
effects were partly offset by slightly negative price effect, driven by lower
raw materials costs and some mix effects.
EBITDA in Performance Materials for the quarter increased 21% compared to Q1
2014. Higher margins were achieved in all businesses, resulting from positive
foreign exchange effects and lower raw material costs. The EBITDA-margin
increased significantly to 13.6%, now in line with the 2015 target range of
13-15%.
EBITDA of DSM Engineering Plastics was substantially up compared to previous
year as a result of good volume growth in combination with increased margins.
DSM Dyneema delivered solid EBITDA growth. EBITDA of DSM Resins & Functional
Materials was slightly up; growth in coating resins was offset by lower results
in functional materials.
Innovation Center
Net sales in Q1 2015 were 6% higher compared to Q1 2014. DSM Biomedical
benefited from a stronger US dollar. Volumes in DSM Biomedical were lower
compared to Q1 2014, mainly due to destocking at a major customer. Furthermore,
Q1 2014 still included the St. Jude royalty revenues, which ended in April 2014.
EBITDA in Q1 2015 improved versus Q1 2014 supported by positive currency
developments, despite the lower royalty income.
Corporate Activities
EBITDA in Q1 2015 was in line with the same period in previous year.
Pharma activities and other associates
Total Q1 2015 sales of joint control entities amounted to ?128 million on a
100% basis (Q1 2014: ?105 million) of which ?117 million from DSM Sinochem
Pharmaceuticals (Q1 2014: ?98 million).
DPx holdings (49% DSM) realized total sales (100%) of ?433 million, from
November 2014 up to and including January 2015, with a corresponding EBITDA
margin of 17%. The net result of DPx was negatively impacted by ?24 million
exceptional items (before tax) related to restructuring, integration and
realizing synergies of the company.
Discontinued operations
Polymer Intermediates and Composite Resins
Net sales amounted to ?506 million, positively impacted by currency effects of
7% and EBITDA amounted to ?38 million. The activities currently in discontinued
operations showed an increase in EBITDA. Polymer Intermediates (higher volumes
and margins) and DSM Composite Resins (higher volumes) both contributed to the
increase. The Q1 2014 discontinued operations also included DSM Pharmaceutical
Products (?102 million sales, -?2 million EBITDA) which is now part of the DPx
joint venture.
Financial overview
Exceptional items
Total exceptional items in the first quarter amounted to a loss of ?163 million
before tax (?145 million after tax). This includes ?137 million (?130 million
after tax) due to the impairment following the announced partnership for Polymer
Intermediates and Composite Resins businesses and ?26 million restructuring and
related expenses.
Net profit
Financial income and expense in Q1 2015 amounted to -?52 million compared to
-?19 million in Q1 2014. The main reason for these higher costs were unfavorable
hedge results amongst others due to a downward shift in the interest curve of
the Swiss franc.
The effective tax rate in Q1 2015 was 18%, in line with the full year 2014.
Net profit, continuing operations before exceptional items in Q1 2015 decreased
by ?22 million compared to Q1 2014 and stood at ?69 million.
Net earnings per ordinary share (continuing operations, before exceptional
items) amounted to ?0.39 in Q1 2015 compared to ?0.52 in Q1 2014.
Cash flow, capital expenditure and financing
Cash provided by operating activities from continuing operations in Q1 2015 was
?84 million (Q1 2014: ?11 million).
Operating working capital, continuing operations expressed as a percentage of
annualized sales amounted to 27.9% compared to 26.3% at year-end 2014. The
operating working capital increased by ?199 million from ?1,903 million at year-
end of 2014 to ?2,102 million at the end of Q1 2015. This was entirely due to
the foreign exchange translation effect. Cash operating working capital from
continuing operations remained flat, contrary to usual seasonality.
Cash used for capital expenditure net of customer funding amounted to ?135
million in Q1 2015 compared to ?146 million in Q1 2014.
Net debt increased by ?512 million compared to year-end 2014 and stood at ?2,932
million by the end of Q1 2015. The increase was mainly driven by the mark-to-
market change in fair value of financial derivatives held.
DSM in motion: driving focused growth
Strategy update
DSM in motion: driving focused growth is the strategy that the company embarked
on in September 2010, which was updated in September 2013. The next update is
planned for Q4 2015.
Improvement programs
The steps DSM is taking to address the ongoing challenging external environment,
including a focus on operational performance and enhancing profitability, are
going to plan. DSM is progressing well with setting up a number of efficiency
improvement and cost reduction programs, especially in Nutrition and across all
support functions of the company. In addition, in 2015 further focus will be
given to improve operating working capital management.
Below are some highlights of DSM's Q1 2015 achievements.
High Growth Economies: from reaching out to being truly global
DSM finalized the previously announced acquisition of Aland, a Hong Kong-based
company producing vitamin C in mainland China. Aland is one of the leading
Vitamin C manufacturers in China with a production facility in Jingjiang,
Jiangsu Province. In 2014 the company realized net sales of about USD 110
million in vitamin C with around 1,800 employees. The transaction excludes
Aland's consumer health activities.
Innovation: from building the machine to doubling innovation output
DSM opened its Nutrition Innovation Center for Asia Pacific in Singapore. It is
an integral part of an expanded DSM Singapore office, alongside similar
facilities located in China, Brazil, Switzerland and the United States. By
extending its global network of innovation expertise, the new center anchors
DSM's status as the world's premier nutrition solutions provider while enhancing
its ability to address the needs of its regional customers.
Sustainability: from responsibility to business driver
DSM published its 2014 Integrated Annual Report. The report is now based on the
G4 guidelines of the Global Reporting Initiative, the fourth generation of
sustainability reporting guidelines.
Acquisitions & Partnerships: from portfolio transformation to driving focused
growth
DSM and CVC Capital Partners announced a partnership for DSM's activities
in Polymer Intermediates (Caprolactam and Acrylonitrile) and Composite
Resins through the formation of a new company, provisionally called NewCo. The
new company will be 65% owned by CVC and 35% by DSM, with 1,950 employees. Pro-
forma third-party sales of NewCo in 2014 amounted to ?2.1 billion with a 2014
EBITDA of ?106 million.
In accordance with the applicable accounting standards, DSM's caprolactam,
acrylonitrile and composite resins businesses are classified as assets held for
sale in Q1 2015 and an initial book loss after tax of ?130 million is recognized
as an exceptional item in Q1 2015. Post-closing, expected in Q3 2015, DSM will
present the investment in NewCo as an associate, accounted in accordance with
the equity method. Re-stated figures have been made available.
DSM finalized the previously announced divestment of Euroresins to Cathay
Investments and the sale of DSM Synres to Standard Investment. Both divestments
are in line with the strategic actions DSM announced in November 2014.
Outlook
Macro-economic uncertainty and low consumer confidence continue to impact market
dynamics. DSM assumes low growth in Europe, continued economic resilience and
growth in the US and a slowdown of growth in some of the high growth economies.
Assuming current low spot prices in vitamin E persist, the negative price impact
on DSM's 2015 EBITDA will be around ?80 million compared to 2014.
The volatility in currencies, including the strengthening of the Swiss franc and
the US Dollar against the Euro, will have a mixed effect on DSM's 2015 results
compared to 2014. Based on current exchange rates and the 2015 hedge effects, an
overall annual positive impact on 2015 EBITDA is estimated at approximately ?45
million, should current rates persist throughout the remainder of the year.
Taking the above into account, DSM aims to deliver an EBITDA in 2015 ahead of
2014, the increase mainly driven by positive foreign exchange effects.
Additional information
Today DSM will hold a conference call for the media from 08.00 AM to 08.30 AM
CET and a conference call for investors and analysts from 09.00 AM to 10.00 AM
CET. Details on how to access these calls can be found on the DSM website,
www.dsm.com. Also, information regarding DSM's Q1 result 2015 can be found in
the Presentation to Investors, which can be downloaded from the Investors
section of the DSM website.
Important dates
Annual General Meeting of Shareholders Thursday, 30 April 2015
Ex-dividend quotation date 2015 Tuesday, 5 May 2015
Report for the second quarter of 2015 Tuesday, 4 August 2015
Report for the third quarter of 2015 Tuesday, 3 November 2015
Capital Markets Day Wednesday, 4 November
2015
Full year results 2015 Wednesday, 17 February
2016
Heerlen, 29 April 2015
The Managing Board
Feike Sijbesma, CEO/Chairman
Geraldine Matchett, CFO
Stefan Doboczky
Stephan Tanda
Dimitri de Vreeze
DSM - Bright Science. Brighter Living.(TM)
Royal DSM is a global science-based company active in health, nutrition and
materials. By connecting its unique competences in Life Sciences and Materials
Sciences DSM is driving economic prosperity, environmental progress and social
advances to create sustainable value for all stakeholders simultaneously. DSM
delivers innovative solutions that nourish, protect and improve performance in
global markets such as food and dietary supplements, personal care, feed,
medical devices, automotive, paints, electrical and electronics, life
protection, alternative energy and bio-based materials. DSM and its associated
companies deliver annual net sales of about ?10 billion with approximately
25,000 employees. The company is listed on Euronext Amsterdam. More information
can be found at www.dsm.com
Or find us on:
For more information:
DSM Corporate Communications DSM Investor Relations
Herman Betten Dave Huizing
tel. +31 (0) 45 5782017 tel. +31 (0) 45 5782864
e-mail media.contacts(at)dsm.com e-mail investor.relations(at)dsm.com
Presentation to Investors PDF:
http://hugin.info/130663/R/1916310/685182.pdf
Press release-PDF:
http://hugin.info/130663/R/1916310/685183.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: DSM N.V. via GlobeNewswire
[HUG#1916310]
Unternehmensinformation / Kurzprofil:
Datum: 29.04.2015 - 07:15 Uhr
Sprache: Deutsch
News-ID 389283
Anzahl Zeichen: 20277
contact information:
Town:
Heerlen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 141 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DSM reports Q1 2015 results"
steht unter der journalistisch-redaktionellen Verantwortung von
DSM N.V. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
